Phorbol Ester Combinations for Shorter Chemotherapy-Induced Cytopenia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, such as chemotherapy and radiation, often cause severe side effects like neutropenia, thrombocytopenia, and anemia due to their impact on rapidly dividing cells, including bone marrow cells, and there is a need for more effective treatments with fewer side effects.

Innovation Solution

The use of phorbol esters, such as TPA, in combination with G-CSF or EPO, to stimulate the production of white blood cells and red blood cells, respectively, thereby reducing the duration of cytopenia symptoms like neutropenia, thrombocytopenia, and anemia.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If phorbol esters are used to stimulate blood cell production, then the duration of cytopenia is reduced, but the potential toxicity and caustic reactions increase

Engineering Contradiction:

Improveduration of cytopeniaVSAvoidtoxicity and caustic reactions

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The patent combines phorbol esters with G-CSF or EPO to create a synergistic treatment approach. This combination allows the phorbol ester to enhance the effect of the growth factors while distributing the toxicities across multiple agents, potentially reducing the overall harmful effects compared to using phorbol esters alone at high doses.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent specifies particular phorbol ester compounds (TPA, PMA) and their dosing parameters in combination with G-CSF or EPO. By controlling the concentration and timing parameters of these compounds, the treatment achieves effective blood cell stimulation while minimizing toxic effects through optimized parameter selection.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If chemotherapy is used to treat cancer, then cancer cells are eradicated, but bone marrow cells are damaged causing cytopenia

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidbone marrow damage and cytopenia

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses phorbol esters, which have historically been associated with tumor promotion, but converts this harmful property into a beneficial effect by utilizing their ability to activate protein kinase C and stimulate blood cell production. This allows the treatment to counteract chemotherapy-induced bone marrow damage while maintaining cancer treatment efficacy.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent employs growth factors (G-CSF, EPO) that can be administered before or during chemotherapy to preemptively stimulate blood cell production, thereby reducing the severity of cytopenia. This preliminary action helps maintain bone marrow function during cancer treatment.

Inventive Principle:

Principle #10Preliminary action

3Quantity of substance

If growth factors like G-CSF are used to treat neutropenia, then white blood cell production is stimulated, but the duration of treatment and cost increase

Engineering Contradiction:

Improvewhite blood cell countVSAvoidtreatment duration

Core Design Contradiction:

Quantity of substanceVSLoss of time

Solution Approach 1:

The patent combines phorbol esters with G-CSF to create a synergistic effect that accelerates white blood cell production. This combination shortens the treatment duration compared to using G-CSF alone, as the phorbol ester enhances the proliferative effect and reduces the time needed to achieve adequate neutrophil recovery.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of phorbol esters with G-CSF or EPO effectively increases neutrophil and platelet counts, and hemoglobin levels, respectively, providing a synergistic effect that shortens the duration of cytopenia and reduces the need for additional treatments.

Implementation Method 1

Phorbol esters are additionally thought to bind to chimaerins, the Ras activator RasGRP, and the vesicle-priming protein Munc-13... Some phorbol esters also induce nuclear factor-kappa B (NF-κB). The most notable physiological property of phorbol esters is their reported capacity to act as tumor promoters... phorbol esters play a key role in activation of protein kinase C, which triggers various cellular responses

Methodology Applied

Scientific EffectProtein kinase C activation:

Implementation Method 2

Cancer treatments generally involve a combination of surgery, chemotherapy, hormonal therapy and/or radiation treatment to eradicate neoplastic cells in a patient... G-CSF in the treatment and reduction of neutropenia

Methodology Applied

Scientific EffectGranulocyte-colony stimulating factor action:

Implementation Method 3

phorbol esters, such as TPA and erythropoeitin (EPO) for the treatment of anemia in patients

Methodology Applied

Scientific EffectErythropoietin action:

Data Source

PatentUS12539289B2Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia

Publication Date: 2026.02.03 BIOSUCCESS BIOTECH CO LTD

AI summary

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia.